Single-stranded phosphorothioate (PS) oligonucleotide medication have proven potential for the remedy of a number of uncommon illnesses. Nevertheless, a barrier to their widespread use is that they exhibit exercise in solely a slender vary of tissues. One technique to circumvent this constraint is to conjugate them to cationic cell-penetrating peptides (CPPs). Though there are a number of examples of morpholino and peptide nucleic acids conjugated with CPPs, there are noticeably few examples of PS oligonucleotide-CPP conjugates.
That is shocking provided that PS oligonucleotides presently characterize the most important class of accepted RNA-based medication, together with Nusinersen, that bears the two’- O -methoxyethyl (MOE) chemistry. On this work, we report a way for in-solution conjugation of cationic, hydrophobic peptides or human serum albumin to a 22-nucleotide MOE-PS oligonucleotide. Conjugates had been obtained in excessive yields and purities. Our findings pave the best way for his or her large-scale synthesis and testing in vivo .
Enteroviruses are ubiquitous mammalian pathogens that may produce gentle to life-threatening illness. We developed a multimodal, fast, correct and economical point-of-care biosensor that may detect nucleic acid sequences conserved amongst 96% of all identified enteroviruses. The biosensor harnesses the physicochemical properties of gold nanoparticles and oligonucleotides to supply colourimetric, spectroscopic and lateral flow-based identification of an unique enteroviral nucleic acid sequence (23 bases), which was recognized via in silico screening. Oligonucleotides had been designed to exhibit particular complementarity in the direction of the goal enteroviral nucleic acid to supply aggregated gold-oligonucleotide nanoconstructs.
Antisense Oligonucleotide-Primarily based Therapeutic towards Menin for Triple-Unfavorable Breast Most cancers Remedy
The tumor suppressor menin has twin capabilities, performing both as a tumor suppressor or as an oncogene/oncoprotein, relying on the oncological context. Triple-negative breast most cancers (TNBC) is characterised by the dearth of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal progress issue receptor 2 (ERBB2/HER2) and is usually a basal-like breast most cancers. TNBC is related to a dismal prognosis and an inadequate response to chemotherapies. Beforehand, menin was proven to play a proliferative position in ER-positive breast most cancers; nevertheless, the capabilities of menin in TNBC stay unknown.
Right here, we have now demonstrated that menin is expressed in numerous TNBC subtypes with the strongest expression within the TNBC Hs 578T cells. The depletion of menin by an antisense oligonucleotide (ASO) inhibits cell proliferation, enhances apoptosis in Hs 578T cells, highlighting the oncogenic capabilities of menin on this TNBC mannequin. ASO-based menin silencing additionally delays the tumor development of TNBC xenografts.
Evaluation of the menin interactome means that menin might drive TNBC tumorigenesis via the regulation of MLL/KMT2A-driven transcriptional exercise, mRNA 3′-end processing and apoptosis. The examine gives a rationale behind the usage of ASO-based remedy, focusing on menin in monotherapy or together with chemo or PARP inhibitors for menin-positive TNBC therapies.
Synthesis of Oligonucleotides Containing trans Mitomycin C DNA Adducts at N6 of Adenine and N2 of Guanine
Mitomycin C, (MC), an antitumor drug, is a DNA alkylating agent presently used within the clinics. Inert in its native type, MC is diminished to reactive mitosenes which endure nucleophilic assault by guanine or adenine bases in DNA to type monoadducts in addition to interstrand crosslinks (ICLs). Though ICLs are thought-about essentially the most cytotoxic lesions, the position of every particular person adduct within the drug’s cytotoxicity remains to be not totally understood. Artificial routes have been developed to entry modified oligonucleotides containing dG MC-monoadducts and dG-MC-dG ICL at a single place of their base sequences to analyze the organic results of those adducts.
Nevertheless, till now, oligonucleotides containing monoadducts fashioned by MC on the adenine base had not been out there, thus stopping the examination of the position performed by these lesions within the toxicity of MC. Right here, we current a path to entry these substrates. Structural proof of the adducted oligonucleotides had been supplied by enzymatic digestion to nucleosides and excessive decision mass spectral evaluation.
Moreover, mother or father oligonucleotides containing a dG monoadduct and a dG-MC-dG ICL had been additionally produced. The soundness and bodily properties of all substrates had been in contrast through CD spectroscopy and UV melting temperature research. Lastly, digital fashions had been created to discover the conformational house and structural options of those MC-DNA complexes.
Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
Antisense oligomers (AOs) are more and more getting used to modulate RNA splicing in stay cells, each for analysis and for the event of therapeutics. Whereas the commonest supposed impact of those AOs is to induce skipping of entire exons, uncommon examples are rising of AOs that induce skipping of solely a part of an exon, via activation of an inside cryptic splice website. On this report, we examined seven AO-induced cryptic splice websites in six genes.
C1orf148 Protein Vector (Human) (pPB-N-His) |
|||
| PV066146 | ABM | 500 ng | Ask for price |
C1orf148 Protein Vector (Human) (pPM-C-HA) |
|||
| PV066147 | ABM | 500 ng | Ask for price |
C1orf148 Protein Vector (Human) (pPM-C-His) |
|||
| PV066148 | ABM | 500 ng | Ask for price |
C1orf148 3'UTR Luciferase Stable Cell Line |
|||
| TU002091 | ABM | 1.0 ml | EUR 1672.8 |
C1orf148 3'UTR GFP Stable Cell Line |
|||
| TU052091 | ABM | 1.0 ml | EUR 1672.8 |
C1orf148 Protein Vector (Human) (pPB-His-MBP) |
|||
| PV329902 | ABM | 500 ng | Ask for price |
C1orf148 Protein Vector (Human) (pPB-His-GST) |
|||
| PV329903 | ABM | 500 ng | Ask for price |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720047 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720051 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV720052 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Protein Vector (Human) (pPM-N-D-C-HA) |
|||
| PV329904 | ABM | 500 ng | Ask for price |
C1orf148 Protein Vector (Human) (pPM-N-D-C-His) |
|||
| PV329905 | ABM | 500 ng | Ask for price |
C1orf148 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0213905 | ABM | 3 x 1.0 ug | EUR 451.2 |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV720048 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV720049 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV720050 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0213906 | ABM | 1.0 ug DNA | EUR 200.4 |
C1orf148 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0213907 | ABM | 1.0 ug DNA | EUR 200.4 |
C1orf148 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0213908 | ABM | 1.0 ug DNA | EUR 200.4 |
CD11b Antibody Antibody |
|||
| ABD2911 | Lifescience Market | 100 ug | EUR 525.6 |
ASAP1 antibody Antibody |
|||
| DF8746 | Affbiotech | 200ul | EUR 420 |
anti- Antibody^Polyclonal antibody control antibody |
|||
| LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Antibody |
|||
| A1360-500 | Biovision | each | Ask for price |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| 20-abx004855 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx008109 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx123734 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx014333 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-400ul | Abbexa | 400 ul | EUR 627.6 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-80l | Abbexa | 80 µl | EUR 343.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx036399-100ug | Abbexa | 100 ug | EUR 469.2 |
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319900 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319901 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319905 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319913 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx230204-100ug | Abbexa | 100 ug | EUR 577.2 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx324434 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx311665 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx234901-100ug | Abbexa | 100 ug | EUR 661.2 |
Anti-Anti-SEPT6 antibody antibody |
|||
| STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
|||
Anti-Anti-SEPT9 Antibody antibody |
|||
| STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
|||
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ111530 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT4 Antibody antibody |
|||
| STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
|||
Anti-Anti-MARCH9 Antibody antibody |
|||
| STJ112609 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ113941 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ114081 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-MARCH8 Antibody antibody |
|||
| STJ114828 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ116214 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ117206 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT12 Antibody antibody |
|||
| STJ117759 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118549 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118550 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH7 Antibody antibody |
|||
| STJ118752 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT3 Antibody antibody |
|||
| STJ118990 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ28365 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ28963 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ25475 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ25477 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ25479 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT1 antibody antibody |
|||
| STJ119580 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
|||
CLCN5 Antibody / CIC-5 antibody |
|||
| RQ6462 | NSJ Bioreagents | 100ug | EUR 419 |
|
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
|||
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-100ul | SAB | 100ul | EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-50ul | SAB | 50ul | EUR 286.8 |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: anti-CD22 monoclonal antibody |
|||
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: anti-CD22 monoclonal antibody |
|||
Antibody Pair to ApoA-V antibody |
|||
| 10R-1876 | Fitzgerald | 100 ul | EUR 781.2 |
|
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
|||
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103034 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103035 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103036 | Abbexa |
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
|||
| abx023924-1mg | Abbexa | 1 mg | EUR 1446 |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319902 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319903 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319904 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319906 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319907 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319908 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319914 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319915 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319916 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319929 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319930 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319931 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
|||
| 20-abx311666 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
|||
| 20-abx311667 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
|||
| 20-abx311668 | Abbexa |
|
|
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
|||
| abx233571-100ug | Abbexa | 100 ug | EUR 577.2 |
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
|||
| abx411057-50ug | Abbexa | 50 ug | EUR 710.4 |
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
|||
| AMM06679G | Leading Biology | 0.05mg | EUR 633.6 |
|
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
|||
Goat anti- human Antibody^Polyclonal antibody |
|||
| LSMab09896 | Lifescience Market | 100 ug | EUR 525.6 |
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D | Stressmarq | 0.1mg | EUR 424.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A390 | Stressmarq | 0.1mg | EUR 481.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A488 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A565 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A594 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A633 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A655 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A680 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A700 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-ALP | Stressmarq | 0.1mg | EUR 472.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-APC | Stressmarq | 0.1mg | EUR 478.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC . |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-APCCY7 | Stressmarq | 0.1mg | EUR 565.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-BI | Stressmarq | 0.1mg | EUR 475.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY350 | Stressmarq | 0.1mg | EUR 496.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY405 | Stressmarq | 0.1mg | EUR 483.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY488 | Stressmarq | 0.1mg | EUR 471.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY594 | Stressmarq | 0.1mg | EUR 474 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY633 | Stressmarq | 0.1mg | EUR 468 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-FITC | Stressmarq | 0.1mg | EUR 470.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-HRP | Stressmarq | 0.1mg | EUR 465.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-P594 | Stressmarq | 0.1mg | EUR 488.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-PCP | Stressmarq | 0.1mg | EUR 478.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-RPE | Stressmarq | 0.1mg | EUR 476.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE . |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-STR | Stressmarq | 0.1mg | EUR 477.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692S | Stressmarq | 0.012mg | EUR 78 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
|||
Anti-Noelin Antibody BIOTIN Antibody BIOTIN |
|||
| STJ501938 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
| STJ501939 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody BIOTIN Antibody BIOTIN |
|||
| STJ501940 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
| STJ501941 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-IgG1 Negative Control Antibody antibody |
|||
| STJ16100881 | St John's Laboratory | 1 mL | EUR 573.6 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20161-100UG | NSJ Bioreagents | 100ug | EUR 409 |
5 of those cryptic splice websites had been found via our personal experiments, and two originated from different revealed experiences. We modelled the anticipated results of AO binding on the secondary construction of every of the RNA targets, and the way these alterations would in flip have an effect on the accessibility of the RNA to splice elements. We noticed {that a} widespread predicted impact of AO binding was disruption of the exon definition sign throughout the exon’s excluded section.